AC220: Clinical Trials

12 trials of AC220, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 3 completed, 3 recruiting, 1 not yet recruiting. 12 Phase 2, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Active not recruiting 3, Completed 3, Recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1
Phase 17Active not recruiting 3, Completed 2, Recruiting 1, Terminated 1

Follow AC220: new trials by email Literature Review of AC220 trials Research Report on AC220

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia
Phase 2Not yet recruitingNational Cancer Institute (NCI)1222027-01-152026-10-07
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2RecruitingNational Cancer Institute (NCI)20002024-06-182026-11-02
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Quizartinib, Etoposide, Dexrazoxane - Acute Myeloid Leukemia in Children
Phase 2RecruitingPrincess Maxima Center for Pediatric Oncology602024-02-062025-08-05
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Azacitidine, Quizartinib - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center302020-07-212026-10-05
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib - Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center522020-05-272026-11-10
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Cladribine, Cytarabine, Idarubicin - Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center802019-10-222026-06-12
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
Quizartinib, Venetoclax - Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center82019-01-252024-09-19
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Decitabine, Quizartinib, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center1292018-10-312026-11-03
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
Quizartinib, Omacetaxine Mepesuccinate Injection - AML, FLT3-ITD Mutation
Phase 2UnknownThe University of Hong Kong402017-10-012020-12-10
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Azacitidine, Cytarabine, Quizartinib - FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center732013-11-122026-10-23
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
AC220 - Leukemia, Myeloid, Acute
Phase 2CompletedDaiichi Sankyo762012-04-012019-12-27
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
Plerixafor, AC220, Ganetespib - Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome
Phase 1 / Phase 2CompletedCardiff University1132011-04-012014-06-11

Conditions studied

Leukemia, Myeloid, Acute (10)  ·  Myelodysplastic Syndromes (5)  ·  Leukemia, Myelomonocytic, Chronic (2)  ·  Myeloproliferative Disorders (2)  ·  Leukemia (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Recurrence (1)

Sponsors

M.D. Anderson Cancer Center (6)  ·  National Cancer Institute (NCI) (2)  ·  Cardiff University (1)  ·  Daiichi Sankyo (1)  ·  Princess Maxima Center for Pediatric Oncology (1)  ·  The University of Hong Kong (1)

Countries

United States (8)  ·  United Kingdom (2)  ·  Canada (1)  ·  France (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Puerto Rico (1)

Top investigators

Musa Yilmaz (3)  ·  Alan K Burnett (1)  ·  Anskar Leung, Professor (1)  ·  Gertjan Kaspers, Prof. Dr. (1)  ·  Guillermo M Bravo (1)  ·  Jerald P Radich (1)  ·  Keith W Pratz (1)  ·  Michel Zwaan, Prof. Dr. (1)  ·  Naval G Daver (1)  ·  Nigel H Russell (1)  ·  Yesid Alvarado, MD (1)

Results publications

PMID 33208914, PMID 36902217, PMID 38744144, PMID 42321916

NIH funding

2023 (1), U10CA180820 (1), U10CA180888 (1)